HUBBARD, Ohio, May 11 /PRNewswire-FirstCall/ -- NanoLogix, Inc. (Pink Sheets: NNLX) is pleased to announce the creation of its Science Advisory Board to help evaluate and target research and development efforts for products. The new advisory board provides the company with a vastly expanded scope of expertise in both medicine and biomedical research.
Dr. Robert Ollar, NanoLogix cofounder and author of numerous NanoLogix patents, has resigned from the NanoLogix Board of Directors to assume the position of Chairman of the Science Advisory Board.
NanoLogix Science Advisory Board Members
Dr. Robert A. Ollar, M. Sc., Ph.D.
Chairman of the Science Advisory Board. Dr. Ollar is the director of the Core Molecular Biology Program of the Department of Surgery at St. Vincent's Hospital in Manhattan. He is also an Assistant Professor at
He brings to the Board decades of experience in the fields of medical microbiology, mycobacteriology, medical mycology, and molecular biology. He serves as advisor to the WHO Global Stop TB Partnership, CDC TB Training and Educational Network, and the Mahatma Gandhi Institute for Medical Sciences in India in the fields of TB and AIDS-related mycobacterial Diseases.
Dr. Ollar's current focus is on the development of molecular technologies for rapid detection of pancreatic and colorectal cancers.
Sergey V. Gazenko, Ph.D., NanoLogix Vice-President of Research and Development. Dr. Gazenko holds his doctoral degree from The Institute of Applied Biochemistry in Moscow. Dr. Gazenko has worked for more than 28 years in the area of microbiological diagnostics and is the author of numerous scientific publications and patents. He is the author of both granted and pate
|SOURCE NanoLogix, Inc.|
Copyright©2009 PR Newswire.
All rights reserved